Glycorex Transplantation AB (publ)
Glycorex Transplantation AB (publ), a medical technology company, focuses on transplantation, blood transfusion, and autoimmune diseases. It develops an antigen-specific immunoadsorption to reduce blood group antibodies and autoantibodies in the blood. The company's principal product is Glycosorb-ABO, which enables blood group incompatible kidney transplantation and is also used to enable heart, … Read more
Glycorex Transplantation AB (publ) (O33) - Total Liabilities
Latest total liabilities as of September 2025: €16.31 Million EUR
Based on the latest financial reports, Glycorex Transplantation AB (publ) (O33) has total liabilities worth €16.31 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Glycorex Transplantation AB (publ) - Total Liabilities Trend (2021–2024)
This chart illustrates how Glycorex Transplantation AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Glycorex Transplantation AB (publ) Competitors by Total Liabilities
The table below lists competitors of Glycorex Transplantation AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hannun SA
MC:HAN
|
Spain | €3.18 Million |
|
Torr Metals Inc
V:TMET
|
Canada | CA$1.80 Million |
|
Avensia publ AB
ST:AVEN
|
Sweden | Skr149.82 Million |
|
Maxindo Karya Anugerah
JK:MAXI
|
Indonesia | Rp144.86 Billion |
|
Capitea S.A.
WAR:CAP
|
Poland | zł308.52 Million |
|
TPC Consolidated Ltd
AU:TPC
|
Australia | AU$39.31 Million |
|
Pico (Thailand) Public Company Limited
BK:PICO
|
Thailand | ฿414.58 Million |
|
Delorean Corporation Ltd
AU:DEL
|
Australia | AU$46.75 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Glycorex Transplantation AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Glycorex Transplantation AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Glycorex Transplantation AB (publ) (2021–2024)
The table below shows the annual total liabilities of Glycorex Transplantation AB (publ) from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €17.19 Million | -21.16% |
| 2023-12-31 | €21.80 Million | +0.42% |
| 2022-12-31 | €21.71 Million | +15.22% |
| 2021-12-31 | €18.85 Million | -- |